Guselkumab Boosts Response in Resistant Psoriatic Arthritis

NEW YORK (Reuters Health) – In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase IIIb trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the University of Oxford, […]
Continue reading »